The Bruckner Group

Bruckner Oncology, also known as The Bruckner Group, is a specialized clinical research and medical oncology center based in New York that focuses on developing novel therapeutic protocols for advanced and refractory cancers. Led by Dr. Howard Bruckner, the group is recognized for its pioneering work in "metronomic" chemotherapy, utilizing low-dose, multi-agent combinations to maximize efficacy while minimizing systemic toxicity. The organization conducts independent clinical trials and has published extensive research on innovative treatment regimens for solid tumors, particularly in pancreatic and ovarian oncology. Their approach centers on overcoming drug resistance through the strategic scheduling and combination of existing FDA-approved therapeutic agents.